DS Research is actively participating as a clinical trial site in the ongoing Phase 3 development program for envudeucitinib, an investigational oral TYK2 inhibitor showing strong potential in the treatment of moderate-to-severe plaque psoriasis. As innovation in plaque psoriasis treatment continues to accelerate, DS Research is proud to support research that is shaping the future… Read More

The treatment landscape for plaque psoriasis is entering a new era—and DS Research is proud to have played a role in making it possible. Recently, Johnson & Johnson announced the FDA approval of ICOTYDE™ (icotrokinra), a first-in-class targeted oral peptide for the treatment of moderate-to-severe plaque psoriasis. You can read the full announcement here: FDA approval press release.… Read More

DS Research has been involved as a clinical research site for many Takeda trials, and we’re excited to share their positive topline results from the pivotal Phase 3 LATITUDE studies of zasocitinib (TAK-279). This is a once-daily oral TYK2 inhibitor for moderate-to-severe plaque psoriasis — with over half of patients achieving nearly clear or clear… Read More

Meet Brandi — one of our incredible alopecia areata patients who’s been using her voice to spread awareness nationwide. In this interview, she shares her journey with alopecia, the challenges it brings, and how treatment completely changed her life. What many don’t see behind the scenes is how clinical trials made this possible. Brandi participated… Read More

Milestone Achievement: FDA Approves ZORYVE® Cream 0.05% for Ages 2–5 We’re proud to share that the U.S. Food and Drug Administration has approved ZORYVE® (roflumilast) cream 0.05% for the treatment of mild to moderate atopic dermatitis in children ages 2 to 5. This is a major step forward for dermatologic care in very young children—and we’re honored to… Read More

DS Research is proud to be a participating site in Veradermics’ ongoing clinical trials evaluating VDPHL01, a first-in-class, non-hormonal oral treatment for androgenetic alopecia (pattern hair loss). These trials represent a significant step forward in addressing hair loss for both men and women. The Phase 2/3 study for male patients is a randomized, double-blind, placebo-controlled trial enrolling approximately 480 participants across 44 sites in… Read More

DS Research was proud to be a participating site in the pivotal clinical trials that led to the FDA approval of Leqselvi™ (deuruxolitinib) for adults with severe alopecia areata. The drug was studied in two large Phase 3 trials—THRIVE-AA1 and THRIVE-AA2—which enrolled over 1,200 patients experiencing significant scalp hair loss. In these trials, participants received 8 mg or 12 mg of Leqselvi twice daily for 24… Read More

We’re proud to share that one of our patients was recently featured in Women’s Health, highlighting the impact of groundbreaking new treatments for alopecia areata—a condition where the immune system mistakenly attacks hair follicles, causing patchy or complete hair loss. The article explores how a new class of medications, known as JAK inhibitors, is offering hope… Read More

2024: A Landmark Year in Dermatology AdvancementsThe field of dermatology has witnessed an exciting leap forward in 2024 with the approval of groundbreaking drugs and devices that are reshaping the treatment landscape for a wide variety of skin conditions. From advanced melanoma therapies to cutting-edge psoriasis and acne treatments, the dermatology sector is benefiting from… Read More